Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy

ARTICLES

Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy

MEDSCAPE

PUBLISHED: 24 FEBRUARY 2020

Early use of the androgen receptor antagonist apalutamide for metastatic castration-sensitive prostate cancer has a sustained carry-over benefit regardless of subsequent therapy, an exploratory analysis of the TITAN trial suggests.